UnknownNot Applicable

Hormones in Hypogonadotropic Hypogonadism

Austria50 participantsStarted 2023-04-02

Plain-language summary

Therefore, the main objective of this prospective pilot study is to evaluate a complete hormonal profile in women with hypogonadotropic hypogonadism, including anti-mullerian hormone (AMH) and antral follicle count. Changes in this regard will be evaluated after 2 months of individual treatment.

Who can participate

Age range18 Years – 35 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient with HH and secondary amenorrhea. HH is defined as absence of spontaneous menstruation for ≥6 months, no abrupt menstrual bleeding after progesterone therapy, and normal or low serum FSH and LH levels. * The patient gave written informed consent to the study after receiving detailed information and education from medical contributors at the Department of Obstetrics and Gynecology, Medical University of Vienna. * Age between \>18 and \<35 years. Exclusion Criteria: * Latent or manifest hypothyroidism (TSH \>4 micromole/milliliter) or current thyroid hormone replacement therapy. * No existing informed consent

What they're measuring

AMH

Timeframe: 2 months

antral follicle count

Timeframe: 2 months

Trial details

NCT IDNCT04927676

SponsorMedical University of Vienna

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06

Contact for this trial

Johannes Ott, MD, PhD

+436504010485 johannes.ott@meduniwien.ac.at

View on ClinicalTrials.gov More AMH trials